Literature DB >> 17693978

Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome.

Michael Maes1, Ivana Mihaylova, Marta Kubera, Eugene Bosmans.   

Abstract

Chronic fatigue syndrome (CFS) is a medically unexplained disorder, characterized by profound fatigue, infectious, rheumatological and neuropsychiatric symptoms. There is, however, some evidence that CFS is accompanied by signs of increased oxidative stress and inflammation in the peripheral blood. This paper examines the role of the inducible enzymes cyclo-oxygenase (COX-2) and inducible NO synthase (iNOS) in the pathophysiology of CFS. Toward this end we examined the production of COX-2 and iNOS by peripheral blood lymphocytes (PBMC) in 18 CFS patients and 18 normal volunteers and examined the relationships between those inflammatory markers and the severity of illness as measured by means of the FibroFatigue scale and the production of the transcription factor nuclear factor kappa beta (NFkappabeta). We found that the production of COX-2 and iNOS was significantly higher in CFS patients than in normal controls. There were significant and positive intercorrelations between COX-2, iNOS and NFkappabeta and between COX-2 and iNOS, on the one hand, and the severity of illness, on the other. The production of COX-2 and iNOS by PBMCs was significantly related to aches and pain, muscular tension, fatigue, concentration difficulties, failing memory, sadness and a subjective experience of infection. The results suggest that a) an intracellular inflammatory response in the white blood cells plays an important role in the pathophysiology of CFS; b) the inflammatory response in CFS is driven by the transcription factor NFkappabeta; c) symptoms, such as fatigue, pain, cognitive defects and the subjective feeling of infection, indicates the presence of a genuine inflammatory response in CFS patients; and d) CFS patients may be treated with substances that inhibit the production of COX-2 and iNOS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17693978

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  24 in total

Review 1.  A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome.

Authors:  Gerwyn Morris; Michael Maes
Journal:  Metab Brain Dis       Date:  2012-06-21       Impact factor: 3.584

2.  Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress.

Authors:  Anil Kumar; Beenta Kumari; Puneet Kumar
Journal:  Neurosci Bull       Date:  2010-02       Impact factor: 5.203

3.  Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients.

Authors:  Cielito C Reyes-Gibby; Jian Wang; Margaret Spitz; Xifeng Wu; Sriram Yennurajalingam; Sanjay Shete
Journal:  J Pain Symptom Manage       Date:  2012-11-11       Impact factor: 3.612

4.  IgM-mediated autoimmune responses directed against anchorage epitopes are greater in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) than in major depression.

Authors:  Michael Maes; Ivana Mihaylova; Marta Kubera; Jean-Claude Leunis; Frank N M Twisk; Michel Geffard
Journal:  Metab Brain Dis       Date:  2012-05-22       Impact factor: 3.584

5.  Neuroprotective mechanism of losartan and its interaction with nimesulide against chronic fatigue stress.

Authors:  Anil Kumar; Barinder Singh; Jitendriya Mishra; Sangeeta Pilkhwal Sah; Raghavender Pottabathini
Journal:  Inflammopharmacology       Date:  2015-06-30       Impact factor: 4.473

6.  A gene signature for post-infectious chronic fatigue syndrome.

Authors:  John W Gow; Suzanne Hagan; Pawel Herzyk; Celia Cannon; Peter O Behan; Abhijit Chaudhuri
Journal:  BMC Med Genomics       Date:  2009-06-25       Impact factor: 3.063

Review 7.  Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways.

Authors:  Michael Maes; Frank N M Twisk
Journal:  BMC Med       Date:  2010-06-15       Impact factor: 8.775

Review 8.  The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression.

Authors:  Michael Maes; Raz Yirmyia; Jens Noraberg; Stefan Brene; Joe Hibbeln; Giulia Perini; Marta Kubera; Petr Bob; Bernard Lerer; Mario Maj
Journal:  Metab Brain Dis       Date:  2008-12-16       Impact factor: 3.584

Review 9.  Nitrosative Stress, Hypernitrosylation, and Autoimmune Responses to Nitrosylated Proteins: New Pathways in Neuroprogressive Disorders Including Depression and Chronic Fatigue Syndrome.

Authors:  Gerwyn Morris; Michael Berk; Hans Klein; Ken Walder; Piotr Galecki; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-06-23       Impact factor: 5.590

Review 10.  Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications.

Authors:  Gerwyn Morris; George Anderson; Michael Berk; Michael Maes
Journal:  Mol Neurobiol       Date:  2013-06-13       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.